Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Cowen Remains Bullish on Ironwood Pharma (IRWD) Following 1Q
May 8, 2017 4:24 PM EDTCowen reiterated an Outperform rating and $20.00 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) following the company's 1Q earnings report. IRWD reported US net sales of $147.6M in 1Q17 which was below the consensus estimates of $172.8M. The miss was driven by seasonality and differences in... More
Ironwood Pharma (IRWD) Misses Q1 EPS by 12c, Sales Miss
May 8, 2017 8:03 AM EDTIronwood Pharma (NASDAQ: IRWD) reported Q1 EPS of ($0.33), $0.12 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $52.2 million versus the consensus estimate of $69.75 million.
LINZESS® (linaclotide) U.S. net sales grew to $148 million in 1Q 2017, primarily driven by more than 20% growth... More
